Posted by Michael Wonder on 11 Feb 2022
U.S. FDA advisers call for new trial of Lilly, Innovent lung cancer drug
10 February 2022 - Innovent Biologics and Eli Lilly should be required to conduct a trial of their lung cancer drug that is applicable to the U.S. population, a panel of advisers to the U.S. Food and Drug Administration recommended Thursday.
The outside advisers voted 14-1 that the agency require more data from the companies, which has only conducted a trial in China.
